Stocks›Healthcare›MGRX

MGRX Mangoceuticals, Inc.

NasdaqResearch view

Mangoceuticals, Inc. operates in the Services-Misc Health & Allied Services, Nec industry.

$0.290−9.69%
Oct 16 close · 1D EOD · Databento
HealthcareServices-Misc Health & Allied Services, NecMicro-capSEC EDGAR FY 2025-12-31

On the WireNo stories on MGRX yet. Follow the company and the next one lands in Following.

The numbers · FY2025, filed

SEC EDGAR
Market cap$6M
Revenue$456,021−26.00%
Net income$-20.6M
EPS, diluted$-2.17+54.80%
Gross margin54.9%
Operating margin-3954.3%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorHealthcare
Market Cap$6.3M
Enterprise Value$4.8M
Income$-20.6M
Sales$456,021
Book/sh$0.70
Cash/sh$0.07
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio1.72
Current Ratio1.74
Debt/Eq—
EPS (ttm)$-2.17
EPS this Y54.8%
EPS past 3/5Y—
Sales past 3/5Y270.9%
EPS Y/Y TTM54.8%
Sales Y/Y TTM-26.0%
Shs Outstand21.57M
ROA-128.3%
ROE-135.8%
ROIC-103.9%
Gross Margin54.9%
Oper. Margin-3954.3%
Profit Margin-4526.8%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$8,939
FY22
$731,493
FY23
$615,873
FY24
$456,021
FY25

Operating leverage — margins

GrossOperatingNet
0%40%80%55%-3954%-4527%FY22FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 4 FY · tap a row to explain it
USDFY2022FY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.